G04CB02 is developed by Fundación Universidad Católica de Valencia San Vicente Mártir.

Last reviewed 2026-04-19 · How we verify

G04CB02

Fundación Universidad Católica de Valencia San Vicente Mártir · Phase 2 active Small molecule

At a glance

Generic name	G04CB02
Sponsor	Fundación Universidad Católica de Valencia San Vicente Mártir
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

G04CB02 CI brief — competitive landscape report
G04CB02 updates RSS · CI watch RSS
Fundación Universidad Católica de Valencia San Vicente Mártir portfolio CI